Taj Distributors

The cream form of ruxolitinib is used to treat a skin condition called eczema (atopic dermatitis) in people who should not use or have not responded to other eczema medications. Eczema is an allergic-type condition that causes red, irritated, and itchy skin.

About This Medicine: The US Food and Drug Administration (FDA) approved ruxolitinib (Opzelura) cream 1.5% for the treatment of nonsegmental vitiligo in adults and pediatric patients 12 years and older, making it the first FDA-approved treatment for repigmentation of the skin in patients with the condition.

Secukinumab is used to treat psoriasis, ankylosing spondylitis, and psoriatic arthritis.^[4][5][6][7] It is given by subcutaneous injection and is sold in a pre-filled syringe or autoinjector that can be used at home and as a lyophilized powder for use in hospitals and clinics.^[5] In October 2023, the FDA approved an intravenous variant of secukinumab.^[8]

Secukinumab was not tested in pregnant women; animal studies did not show harm at relevant doses. The US Food and Drug Administration advises that the drug should be used in pregnant women only if the risk to the fetus is justified by the potential benefit;^[5] the European Medicines Agency (EMA) advises that women should not become pregnant while taking it.^[4]